Diabetes

MUMBAI, India, March 6, 2023 /PRNewswire/ -- Fitterfly, a leading Indian health-tech company, working in the area of diabetes & metabolic health, recently showcased data from its Digital Therapeutics Technology platform at the 16th…

RALEIGH, N.C., Feb. 21, 2023 /PRNewswire/ -- A new study indicates that the GlycoMark blood test identifies high-risk, asymptomatic patients with prediabetes, not detected by standard diabetes tests, hemoglobin A1C and glucose  – a critical…

<!-- Name:DistributionId Value:8742190 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

Newton Biocapital II Leads Funding Round For First-of-Its-Kind Drug to Treat Insulin Resistance First Breakthrough Addressing Insulin Resistance in Type 2 Diabetes Treatment STRASBOURG, France, Jan. 23, 2023 (GLOBE NEWSWIRE) --  …

PRESS RELEASE Indigo Diabetes Business Update SHINE clinical trial enrolment progressing well following positive results from the GLOW early feasibility trialSeveral key senior appointments made in Europe and the US, reflecting the…

PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10 million to Sosei Heptares TOKYO…

New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible to receive US$37 million upfront in…

SAN FRANCISCO, Dec. 6, 2022 /PRNewswire/ -- The diaTribe Foundation, Advanced Technologies & Treatments for Diabetes (ATTD), and the Time in Range Coalition announced today a new international consensus regarding continuous glucose…

The study found  Dia Free Juice effective in reducing Fasting Blood Sugar (FBS) and Post-Prandial Blood Sugar (PPBS) values by up to 30% within 3 Months of consumptionNEW DELHI, Nov. 30, 2022 /PRNewswire/ -- Kapiva, a homegrown Ayurveda…

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy announces that it will begin dispensing TZIELD™ (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2…